Summary of events during year-end report 2019 Twelve months (2019-01-01 – 2019-12-31) · Net sales amounted to SEK 0 (SEK 0). · Result after financial items amounted to  SEK -6 189 903 (SEK -4 189 311). · Earnings per share amounted to SEK  -0,81 (SEK -0,76). · Solidity amounted to 93,0 % (96,5 %). Fourth quarter (2019-10-01 – 2019-12-31) · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to SEK -2 844 273 (SEK -2 131 958). · Earnings per share amounted to SEK -0,37 (SEK -0,39) Earnings per share: Result for the period divided by 7,633,415 shares as of 2019-12-31  Solidity: Equity divided by total capital. Amounts in brackets: Corresponding period in the previous year. "The Company" and "Alzinova" refers to Alzinova AB, reg.no/org.nr. 556861-8168. For more information, please contact Kristina Torfgård, VD tel: +46 708 46 79 75 E-mail: kristina.torfgard@alzinova.com Certified Adviser Corpura Fondkommission AB E-mail: ca@corpura.se tel: 0768-532822 Home page: www.corpura.se About Alzinova AB   Alzinova AB is engaged in pharmaceutical research and development for treatment of Alzheimer’s disease – one of our major health scourges, without efficient treatment options. The Company's patented technology enables the development of novel therapies, that with high precision could target the substances involved in the formation of the disease and render them harmless. Alzinova's focus is to develop a vaccine as a long-acting therapy for treatment and prevention of Alzheimer's disease. The vaccine is under preclinical development, in preparation for human clinical trials. Alzinova was founded by researchers from the MIVAC research center at the University of Gothenburg, and by GU Ventures AB.